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Abstract 
Background: Although alterations in not only the pain sensitivity but also the analgesic effects of opioids have been 
reported under conditions of stress, the influence of unpredictable chronic mild stress (UCMS) on the antinocicep-
tive effects of opioid analgesics remains to be fully investigated. The present study examined the influence of UCMS 
on the thermal pain sensitivity and antinociceptive effects of two opioid analgesics, morphine (an agonist of opioid 
receptors) and tramadol (an agonist of μ-opioid receptor and an inhibitor of both noradrenaline and serotonin 
transporters). We also examined the effects of pretreatment with maprotiline (a noradrenaline reuptake inhibitor) 
and escitalopram (a serotonin reuptake inhibitor) on the antinociceptive action of morphine in mice under an UCMS 
condition.
Results: Unpredictable chronic mild stress did not affect the basal thermal pain sensitivity in a mouse hot-plate test. 
Although morphine dose-dependently induced thermal antinociceptive effects under both the UCMS and non-stress 
conditions, the thermal antinociceptive effect of 3 mg/kg morphine under the UCMS condition was significantly 
lower than under the non-stressed condition. Unlike the case with morphine, we observed no significant difference 
in the thermal antinociceptive effect of tramadol between the UCMS and non-stress conditions. Furthermore, the 
reduced thermal antinociceptive effect of 3 mg/kg morphine under the UCMS condition was significantly amelio-
rated by pretreatment with 10 mg/kg maprotiline but not 3 mg/kg escitalopram. Pretreatment with neither mapro-
tiline nor escitalopram alone was associated with an antinociceptive effect under either condition.
Conclusions: We demonstrated that the antinociceptive effect of morphine but not tramadol was reduced in mice 
that had experienced UCMS. The reduced antinociceptive effect of morphine under the UCMS condition was amelio-
rated by pretreatment with maprotiline but not escitalopram. These results suggest that the reduced antinociceptive 
effects of morphine under conditions of chronic stress may be ameliorated by activation of the noradrenergic but not 
the serotonergic system.
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Background
Endogenous opioid systems play important roles in the 
modulation of pain sensitivity and stress responses. On 
the other hand, various types of stressors have been 
known to alter not only pain sensitivity but also the anal-
gesic effects of opioids [1]. Several studies have demon-
strated the potentiation of the antinociceptive effects of 
opioid analgesics by acute stress, such as restraint stress 
and cold-water swim stress [1–3], whereas other reports 
have shown the attenuation of the antinociceptive effect 
of morphine by chronic stress, such as chronic restraint 
stress and chronic cold-water swim stress [4, 5]. How-
ever, the mechanisms underlying the reduced antinoci-
ceptive effect of morphine under conditions of chronic 
stress remain to be elucidated.
Opioid analgesics, such as morphine and tramadol, are 
used widely for the treatment of moderate to severe pain. 
Morphine is the most widely used ancient opioid analge-
sic and is known to exert analgesic effects by acting on 
μ-opioid receptors [6–8]. Tramadol, a racemic mixture 
of two enantiomers, is one of the most widely used weak 
opioid analgesics. Its major metabolite, (+)-O-desmeth-
yltramadol (M1), acts on opioid receptors as an agonist 
[9–11]. Furthermore, (+)- and (−)-tramadol enantiomers 
inhibit neuronal reuptakes of serotonin and noradrena-
line, respectively [12–14]. We previously showed that the 
thermal antinociceptive effects of tramadol were medi-
ated primarily by its actions on μ-opioid receptors and 
noradrenalin transporters but not on serotonin trans-
porters [9]. Because little is known about the influences 
of monoaminetransporters on the analgesic effects of 
opioids under conditions of chronic stress, we compared 
the antinociceptive effects of morphine and tramadol 
in mice under conditions of unpredictable chronic mild 
stress (UCMS).
Results
Dose–response relationships in the thermal antinoci-
ceptive effects of morphine were examined under the 
UCMS and non-stress conditions (Fig.  1). We found no 
significant differences in the hot-plate latencies under the 
UCMS (23.1 ± 1.5 s) and non-stress (20.6 ± 1.6 s) con-
ditions before drug treatment (Fig.  1a), indicating that 
the UCMS procedure used in the present study did not 
affect the basal thermal pain sensitivity. Morphine dose-
dependently produced thermal antinociceptive effects in 
a hot-plate test under both UCMS and non-stress con-
ditions. A two-way repeated-measures analysis of vari-
ance (ANOVA) revealed that the thermal antinociceptive 
effects of morphine (%MPE) significantly differed under 
the UCMS and non-stress conditions (stress, F1,26 = 5.72, 
p =  0.024; dose, F2,52 =  78.22, p  <  0.001; stress ×  dose 
interaction, F2,52 = 2.81, p = 0.070; Fig. 1b). The thermal 
antinociceptive effect of 3  mg/kg morphine was signifi-
cantly lower under the UCMS than the non-stress con-
dition (p  <  0.01, Sidak’s multiple comparisons post hoc 
test). In contrast, we observed no significant differences 
between these two conditions in the antinociceptive 
effects of lower (1 mg/kg) and higher (10 mg/kg) doses of 
morphine.
Next, dose–response relationships in the thermal 
antinociceptive effects of tramadol were examined under 
the UCMS and non-stress conditions (Fig. 2). We found 
no significant difference in the hot-plate latency between 
the UCMS (21.7 ±  2.0  s) and non-stress (23.7 ±  3.1  s) 
conditions before drug-treatment (Fig.  2a). Tramadol 
dose-dependently produced thermal antinociceptive 
effects in a hot-plate test under both the UCMS and non-
stress conditions. Unlike the case of morphine, no signifi-
cant differences in the antinociceptive effects of tramadol 
were observed under the UCMS and non-stress condi-
tions (Fig. 2b).
Fig. 1 Thermal antinociceptive effects of morphine under the UCMS 
condition. The effects of morphine on thermal nociceptive latency 
(a) and %MPE (b) in a hot-plate test under the UCMS (closed circles 
n = 15) and non-stress (open circles n = 13) conditions. Intraperito-
neal morphine was repetitively administered to the mice at doses of 
1, 2, and 7 mg/kg, for cumulative doses of 1, 3, and 10 mg/kg, respec-
tively. ##p < 0.01, #p < 0.05, significantly differed from the non-stress 
condition. Data are expressed as mean ± SEM.
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We further examined whether pretreatment with 
maprotiline (a noradrenalin reuptake inhibitor) or esci-
talopram (a serotonin reuptake inhibitor) affects the 
reduced antinociceptive effect of morphine (3 mg/kg) on 
mice that had experienced UCMS (Figs. 3, 4).
Pretreatment with maprotiline [3 and 10 mg/kg, intra-
peritoneal (i.p.)] itself did not exert any antinociceptive 
effects under either the UCMS or non-stress condition 
(ANOVA: UCMS, F2,35  =  0.26, p  =  0.77; non-stress, 
F2,37 =  0.43, p =  0.65: Fig.  3a). The thermal antinocic-
eptive effects of morphine were significantly affected 
by pretreatment with maprotiline under the UCMS 
condition (ANOVA: F2,35 =  7.20, p =  0.0024: Fig.  3b). 
The reduced thermal antinociceptive effect of 3  mg/kg 
morphine under the UCMS condition was significantly 
ameliorated by pretreatment with 10  mg/kg mapro-
tiline (p  <  0.05, Sidak’s multiple comparisons post hoc 
test). Pretreatment with maprotiline did not affect the 
antinociceptive effects of morphine (3 mg/kg) under the 
non-stress condition (ANOVA: F2,37  =  0.04, p  =  0.96: 
Fig. 3b).
Pretreatment with escitalopram (1 and 3  mg/kg, i.p.) 
itself did not exert any antinociceptive effects under 
either the UCMS or non-stress condition (ANOVA: 
UCMS, F2,30  =  0.31, p  =  0.74; non-stress, F2,29  =  0.08, 
p = 0.92: Fig. 4a). In contrast to the case of maprotiline, 
pretreatment with escitalopram did not affect the antino-
ciceptive effects of morphine (3 mg/kg) under the UCMS 
and non-stress conditions (ANOVA: UCMS, F2,30 = 0.36, 
p = 0.70; non-stress, F2,29 = 0.23, p = 0.79: Fig. 4b).
Discussion
The present study used mice that had experienced 
UCMS to demonstrate the reduced antinociceptive 
effects of morphine under the chronic stress condi-
tion. It has been reported that chronic stress attenu-
ates the antinociceptive effect of morphine. Specifically, 
da Silva Torres et  al. [4] showed that chronic restraint 
stress attenuated the antinociceptive effect of morphine 
in rats. Girardot and Holloway [5] showed that chronic 
cold-water swim stress reduced the analgesic effect of 
Fig. 2 Thermal antinociceptive effects of tramadol under the UCMS 
condition. The effects of tramadol on thermal nociceptive latency 
(a) and %MPE (b) in a hot-plate test under the UCMS (closed circles 
n = 8) and non-stress (open circles n = 8) conditions. Intraperitoneal 
tramadol was repetitively administered to the mice at doses of 10, 
20, and 70 mg/kg, for cumulative doses of 10, 30, and 100 mg/kg, 
respectively. Data are expressed as mean ± SEM.
Fig. 3 Effects of maprotiline on the antinociceptive effect of 
morphine under the UCMS condition. The effects of maprotiline 
on the thermal pain sensitivity (a) and the antinociceptive effect of 
morphine (3 mg/kg; b) in a hot-plate test under the UCMS (white 
column vehicle, n = 12; gray column maprotiline 3 mg/kg, n = 12; 
black column maprotiline 10 mg/kg, n = 14) and non-stress (white 
column vehicle, n = 14; gray column maprotiline 3 mg/kg, n = 12; 
black column maprotiline 10 mg/kg, n = 14) conditions. *p < 0.05, 
significantly differed from vehicle-injected UCMS mice. Data are 
expressed as mean ± SEM.
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morphine in rats. The present study has added UCMS 
to the list of chronic stressors that attenuate morphine-
induced analgesia.
In the present study, UCMS did not affect basal ther-
mal pain sensitivity in a hot-plate test, although several 
previous studies reported a facilitative or suppressive 
influence of chronic stress on pain sensitivity [15–18]. 
Imbe et  al. [16] reported that chronic restraint stress 
induced hyperalgesia in a tail flick test. Pinto-Ribeiro 
et  al. [17] found reduced nociception in rats submitted 
to a chronic unpredictable stress paradigm using a tail-
flick test. Shi et  al. [18] reported increased thermal and 
mechanical nociceptive thresholds in rats exposed to 
UCMS using a hot plate test and a von Frey test, respec-
tively, although their procedure for UCMS differed from 
ours. These findings suggest that the effects of chronic 
stress on pain sensitivity depend on the stress-inducing 
procedures. Further studies are required to elucidate the 
distinct morphological and functional changes in the 
central nervous system caused by each stress-induction 
procedure.
Unlike the case of morphine, the antinociceptive effect 
of tramadol was not reduced under the UCMS condition. 
In the context of previous reports that tramadol has inhib-
itory effects on noradrenaline and serotonin transporters 
in addition to its agonistic effect on opioid receptors [12–
14], this result suggests the important role of inhibitory 
effects on the transporters in the antinociceptive effect of 
tramadol under UCMS condition. Thus, we examined the 
effects of pretreatment with noradrenaline and serotonin 
transporter inhibitors and found that pretreatment with 
a noradrenaline reuptake inhibitor but not a serotonin 
reuptake inhibitor ameliorated the reduced antinocicep-
tive effect of morphine under the UCMS condition. Doses 
of serotonin transporter inhibitor (escitalopram; 1, 3 mg/
kg) used in the present study are thought to be sufficient 
for behavioral experiments [19]. Thus, these results sug-
gest that the reduced antinociceptive effect of morphine 
under the UCMS condition may be due to the down-
regulation of noradrenergic transmission. In this context, 
Chen et al. [20] reported that chronic social defeat stress 
increased the expression of noradrenalin transporter 
mRNA and protein in the locus coeruleus (LC), which 
supposedly down-regulated noradrenergic transmission. 
Additionally, the electrophysiological study conducted by 
Bravo et al. [21] showed that chronic mild stress induced 
reduction in noradrenergic transmission in the LC.
It is thought that chronic pain itself also constitutes 
chronic stress. It has been reported that chronic pain 
induces dysfunction in the noradrenergic transmission 
in the LC of rats in the neuropathic pain model [22]. 
Combined with a series of previous findings, the present 
results suggest that compounds having both an agonis-
tic effect on opioid receptors and an inhibitory effect on 
noradrenaline transporters, or a combination of opioids 
and noradrenaline reuptake inhibitors, may be effective 
in the treatment of patients suffering from chronic pain. 
In support of this notion, antidepressants with an inhibi-
tory effect on noradrenaline transporters (e.g., seroto-
nin–noradrenaline reuptake inhibitors (SNRIs), tricyclic 
antidepressants) have been reported to be more effective 
than selective serotonin reuptake inhibitors (SSRIs) for 
the treatment of chronic pain [23].
Conclusions
The antinociceptive effects of morphine but not trama-
dol were reduced under the UCMS condition. Pretreat-
ment with a noradrenaline transporter inhibitor but not a 
serotonin transporter inhibitor ameliorated the reduced 
antinociceptive effect of morphine under the UCMS 
condition. These results suggest that activation of the 
noradrenergic but not the serotonergic system may ame-
liorate the reduced antinociceptive effect of morphine 
under conditions of chronic stress.
Fig. 4 Effects of escitalopram on the antinociceptive effect of 
morphine under the UCMS condition. The effects of escitalopram 
on the thermal pain sensitivity (a) and the antinociceptive effect of 
morphine (3 mg/kg; b) in a hot-plate test under the UCMS (white col-
umn vehicle, n = 11; gray column escitalopram 1 mg/kg, n = 12; black 
column escitalopram 3 mg/kg, n = 10) and non-stress (white column 
vehicle, n = 12; gray column escitalopram 1 mg/kg, n = 11; black 
column escitalopram 3 mg/kg, n = 9) conditions. Data are expressed 
as mean ± SEM.
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Methods
Animals
Male BALB/c mice (Japan SLC, Hamamatsu, Japan) were 
used. The mice were maintained at a constant ambient 
temperature (23 ± 1°C) under a 12/12-h light/dark cycle 
with food and water available ad  libitum. Three mice 
were bred in one cage (17 × 35 cm cage). All experiments 
were performed with the approval of the Institutional 
Animal Care and Use Committee at Hokkaido University.
Drugs
Tramadol hydrochloride was gifted by Nippon Shinyaku 
Co., Ltd (Kyoto, Japan); morphine hydrochloride was 
purchased from Takeda Pharmaceutical Company, Ltd. 
(Osaka, Japan); maprotiline hydrochloride was purchased 
from Wako Pure Chemical Ind., Ltd (Osaka, Japan); and 
escitalopram oxalate was purchased from SIGMA Chem-
ical Co. (St. Louis, MO).
Unpredictable chronic mild stress (UCMS)
As shown in Table 1, mice experienced one of the stress-
ors each day during a 5-week period (Table 1). The fol-
lowing stressors were applied: cage tilting (45°), damp 
bedding (200-ml water/cage), food deprivation, food and 
water deprivation, lights on overnight, small cage (change 
in size to 12.5 × 20 cm), cage-mate shuffle, lights off dur-
ing the day, and cage exchange (changing the cage to one 
used by other mice).
Antinociceptive test
A hot-plate test was performed according a slightly 
modified version of the method developed by Woolfe 
and MacDonald [24]. A commercially available appara-
tus consisting of an acrylic resin cylinder (ϕ20 × 25 cm, 
diameter × height) and a thermo-controlled aluminum 
plate (Model MK-350HC, Muromachi Kikai Co., Tokyo, 
Japan) was used. Mice were placed on a 52 ± 0.5°C hot 
plate, and latencies to hind-paw licking or jumping 
were recorded with a cut-off time of 60 s. The analyses 
of dose-dependency were conducted by the cumulative 
dose–response schedule [25], in which the 3 doses of 
drugs are administered to the same mouse and hot-
plate tests was performed 4 times (pre and after drug 
injections) in the present study. Morphine was repeti-
tively administered to the mouse by i.p. injection at 
doses of 1, 2, and 7 mg/kg, for cumulative doses of 1, 3, 
and 10  mg/kg, respectively. Tramadol was repetitively 
administered to the mouse by i.p. injection at doses of 
10, 20, and 70  mg/kg, for cumulative doses of 10, 30, 
and 100 mg/kg, respectively. Hot-plate tests were per-
formed 30 min after each injection. Each injection was 
administered immediately after the test. In the analyses 
using noradrenalin or serotonin transporter inhibitors, 
maprotiline (3, 10 mg/kg, i.p.) or escitalopram (1, 3 mg/
kg, i.p.) was administered 30  min before the injection 
of morphine (3.0 mg/kg). Each datum regarding latency 
was converted to the percent of the maximal possible 
effect (%MPE) according to the following formula:
Statistical analyses
Antinociceptive effects were statistically evaluated by 
ANOVA followed by the Sidak’s multiple-comparisons 
post hoc test using GraphPad Prism v.6.00 (GraphPad 
Software, San Diego, CA). P values <0.05 were consid-
ered to indicate statistical significance.
Abbreviations
ANOVA: analysis of variance; i.p.: intraperitoneal; LC: locus coeruleus; MPE: 
maximal possible effect; UCMS: unpredictable chronic mild stress.
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%MPE = (post-drug latency− pre-drug latency)/
(cut-off time − pre-drug latency) × 100%.
Table 1 Procedures and schedule of UCMS
Stressor Duration (h) Day of application
1 Cage tilting (45°) 14 1, 9, 17, 27
2 Damp bedding 24 2, 14, 21, 30, 34
3 Food deprivation 24 3, 15, 20, 28, 33
4 Food and water deprivation 14 6, 12, 24
5 Lights on overnight 24 4, 19, 25, 32
6 Small cage 24 7, 18, 29, 35
7 Cage mate shuffle 24 5, 13, 31
8 Lights off during the day 24 8, 16, 22
9 Cage exchange 24 10, 23
10 Non stress 11, 26
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